Completed Enrollment

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (ACHIEVE-3)

J2A-MC-GZGU -

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
Orforglipron, Semaglutide
Could I receive a Placebo?
No
Enrollment Goal
1576
Trial Dates
Sep 22, 2023 - Jul 2025
How long will I be in the trial?
The study will last about 61 weeks and may include up to 13 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have Type 2 Diabetes

  • Are of Stable Body Weight for at least 90 days prior to screening

  • Agree to not begin a strict diet or exercise program during the study

Participants Must Not:

  • Have Type 1 Diabetes

  • Have a history of ketoacidosis or hyperosmolar state or coma the last 6 months before screening

  • Have Congestive Heart Failure

  • Have acute or chronic hepatitis

  • Have history of cancer or in remission less than 5 years

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources

Diabetes Research

To learn more about diabetes and ongoing clinical trials in this area, visit our Diabetes Research page.

Clinical Trial Information

A clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.